Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit was initiated following a press release on August 9, 2024, where Pacira announced the invalidation of its U.S. Patent No. 11,033,495 related to its main product Exparel, which constitutes approximately 80% of the company's revenue [2] - The invalidation of the '495 patent raises concerns about the validity of other patents held by Pacira, potentially leading to increased competition from generic products and higher litigation costs [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Company Overview - Pacira BioSciences, Inc. (NASDAQ: PCRX) is primarily known for its product Exparel, which constitutes approximately 80% of its revenue [1]. Legal Issues - A lawsuit against eVenus resulted in the court ruling that Pacira's U.S. Patent No. 11,033,495 (the '495 patent) is not valid, meaning eVenus is not infringing on it [1]. - The invalidation of the '495 patent raises concerns about the validity of Pacira's other patents, potentially leading to more generic competitors entering the market and increased litigation costs [1]. Stock Performance - Following the announcement of the patent invalidation, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Legal Representation - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful business practices [3].

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 2, 2023, and August 8, 2024, following the invalidation of a key patent that significantly impacts its revenue [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by the alleged fraud during the specified period [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition from generics [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2024 on February 27, 2025, after U.S. market close, followed by a live conference call [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA®: an extended-release injection for osteoarthritis knee pain management [3] - ioveraº®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has adversely affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit is a response to a press release issued by Pacira on August 9, 2024, which announced the invalidation of its U.S. Patent No. 11,033,495 related to Exparel, a product that generates approximately 80% of the company's revenue [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has significantly impacted its stock price following the invalidation of a key patent [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for investors affected by alleged securities fraud between August 2, 2023, and August 8, 2024 [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, crucial for its product Exparel, was ruled invalid by the court, impacting approximately 80% of the company's revenue [1]. - The invalidation raises concerns about the validity of other patents held by Pacira, potentially allowing more generic competitors to enter the market [1]. Stock Performance - Following the announcement of the patent ruling, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2].

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=127847&from=4CLASS PERIOD: Augus ...

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit ...